Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible; HIV testing is not required for inclusion in this study
Known history of human immunodeficiency virus (HIV); testing is not required in the absence of prior documentation or known history; HIV-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals are ineligible
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination anti-retroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Individuals who are known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive individuals are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
HIV positive individuals on combination antiretroviral therapy are ineligible
Participants known to be human immunodeficiency virus (HIV)-positive are excluded (Note: HIV testing is not required prior to enrollment). HIV-positive individuals on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are eligible so long as they meet all other criteria; known HIV-positive individuals who are not on combination antiretroviral therapy are not eligible
Known human immunodeficiency virus (HIV)-positive individuals are ineligible
Participants known to be human immunodeficiency virus (HIV)-positive are excluded (note: HIV testing is not required prior to enrollment); HIV-positive individuals on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Negative human immunodeficiency virus (HIV) blood test within 21 days of study entry; HIV-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible; HIV testing is required only for patients deemed to be high-risk
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
HIV-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
PHASE II: Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are eligible so long as they meet all other criteria; HIV-positive individuals who are not on combination antiretroviral therapy are not eligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
HIV-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are eligible so long as they meet all other criteria; HIV-positive individuals who are not on combination antiretroviral therapy are not eligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are eligible for enrollment and will be monitored closely for potential pharmacokinetic interactions with neratinib
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
HIV-positive individuals on combination antiretroviral therapy are ineligible
EXPANSION COHORT ONLY: HIV-positive individuals on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive individuals are ineligible
Known HIV-positive individuals on combination antiretroviral therapy.
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible; HIV-positive individuals on highly active antiretroviral therapy (HAART) will be considered eligible if they have demonstrated good compliance and have a cluster of differentiation (CD)4 count > 500
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible
HIV-positive individuals on combination antiretroviral therapy.
HIV-positive individuals on combination antiretroviral therapy.
HIV-positive individuals on combination antiretroviral therapy.